Autolus Therapeutics
AUTL
67 hedge funds and large institutions have $229M invested in Autolus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 26 reducing their positions, and 15 closing their positions.
2,380% more call options, than puts
Call options by funds: $248K | Put options by funds: $10K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 73 → 67 (-6)
13.6% less ownership
Funds ownership: 72.12% → 58.53% (-14%)
16% less capital invested
Capital invested by funds: $272M → $229M (-$42.8M)
31% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 26
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.63M |
| 2 |
LCP
LGT Capital Partners
Pfaeffikon,
Switzerland
|
+$2.1M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.09M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.61M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$19.4M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$7.97M |
| 3 |
SG Americas Securities
New York
|
-$1.3M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$726K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$712K |
AUTL Hedge Fund Activity: Q1 2022 in Review
67 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2022, worth a combined $229M — down 16% from $272M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of AUTL and 9 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 18 added.
The largest buyer was Citadel Advisors, adding an estimated $7.63M. The largest seller was Frazier Management, exiting entirely with an estimated $19.4M sold.
- 67 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2022, down from 73 in Q4 2021.
- Funds reported $229M of Autolus Therapeutics stock for Q1 2022, down 16% quarter-over-quarter.
- 9 funds opened new Autolus Therapeutics positions in Q1 2022 and 15 closed out, a net change of -6 holders.
- The largest Autolus Therapeutics buyer in Q1 2022 was Citadel Advisors, an estimated $7.63M added.
- The largest Autolus Therapeutics seller in Q1 2022 was Frazier Management, an estimated $19.4M sold.
Based on aggregated 13F filings for Q1 2022.